Short Interest in Kineta, Inc. (NASDAQ:KA) Decreases By 8.1%

Kineta, Inc. (NASDAQ:KA) saw a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 100,700 shares, a drop of 8.1% from the October 15th total of 109,600 shares. Based on an average daily volume of 28,200 shares, the short-interest ratio is presently 3.6 days. Currently, 1.5% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Kineta in a research note on Monday, August 21st.

Kineta Stock Performance

Kineta stock traded up $0.08 during trading on Friday, hitting $3.33. The company’s stock had a trading volume of 13,021 shares, compared to its average volume of 24,214. The stock’s fifty day moving average is $3.29 and its 200 day moving average is $2.87. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.03 and a current ratio of 1.03. Kineta has a 1-year low of $1.78 and a 1-year high of $15.54.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of KA. Colony Group LLC acquired a new stake in Kineta during the second quarter worth about $359,000. Armistice Capital LLC lifted its position in Kineta by 6.2% during the third quarter. Armistice Capital LLC now owns 930,000 shares of the company’s stock valued at $3,162,000 after buying an additional 54,000 shares in the last quarter. Renaissance Technologies LLC grew its stake in Kineta by 111.5% during the first quarter. Renaissance Technologies LLC now owns 37,051 shares of the company’s stock worth $123,000 after buying an additional 19,535 shares during the period. BlackRock Inc. increased its position in shares of Kineta by 236.4% in the second quarter. BlackRock Inc. now owns 20,741 shares of the company’s stock worth $54,000 after acquiring an additional 14,575 shares in the last quarter. Finally, CIBC Asset Management Inc acquired a new stake in shares of Kineta in the first quarter worth $45,000. Institutional investors and hedge funds own 13.66% of the company’s stock.

About Kineta

Kineta, Inc, a clinical-stage biotechnology company, develops immunotherapies in the field of immuno-oncology, cancer, neurology, and arenaviruses. The company is developing KVA12123, an anti-VISTA antagonist mAb immunotherapy, which is in Phase 1/2 clinical trials for the treatment of solid tumors, including non-small cell lung cancer, ovarian cancer, colorectal cancer, colon cancer, pancreatic cancer, and gastric cancer.